Raiffeisen Bank International AG engages in the provision of banking and financial solutions. The company serves commercial customers and financial institutions in Austria and Central and Eastern Europe through its network of subsidiary banks, leasing companies and specialized financial service providers. The company operates through five segments: Central Europe, which encompasses Czech Republic, Hungary, Poland, Slovakia; Southeastern Europe, comprising Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Kosovo, Romania and Serbia; Eastern Europe, encompassing Belarus, Russia and Ukraine; Group Corporates & Markets, which covers operations in Austria, including Austrian and international corporate customers, business with the RBG and specialized financial institution subsidiaries, and Corporate Center segment includes areas: Liquidity management and balance sheet structure management, equity participation management, the banking operations carried out head office.
Raiffeisen Bank International AG의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
TScan Therapeutics Inc 주요 수익원은 T Cell Receptor-engineered T Cell이며, 최신 수익 발표에서 수익은 2,816,000입니다. 지역별로는 United States이 TScan Therapeutics Inc의 주요 시장이며, 수익은 2,816,000입니다.
Raiffeisen Bank International AG은 수익성이 있나요?
no, 최신 재무제표에 따르면 TScan Therapeutics Inc의 순손실은 $0입니다.